Real-World Data Shows Less Benefit for Mesothelioma from Checkpoint Inhibitors Vs. Clinical Trials
Approximately 10% of “real-world” patients with malignant pleural mesothelioma (MPM) benefitted from checkpoint inhibitor therapy with nivolumab, according to the results of a trial presented by Robert A. Belderbos, MD, […] Read more
Real-World Data Show That Survival Just as Good With Carboplatin Therapy as With Cisplatin Therapy in Malignant Pleural Mesothelioma
Kara Nyberg, PhDThe largest real-world cohort study of individuals with malignant pleural mesothelioma (MPM) found a median survival duration of 8 months regardless of whether patients received first-line treatment with cisplatin-based chemotherapy […] Read more
A Holistic Approach to Patient Care
Lauren Evoy DavisTreating the whole patient, not just the disease, is a basic tenet of holistic care. Understanding the physical, emotional, and spiritual needs of patients can help providers provide optimal care […] Read more
TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC
Beth Fand IncollingoThe combination of an anti-angiogenic tyrosine kinase inhibitor (TKI) and an anti-PD-1 immunotherapy proved promising, regardless of PD-L1 expression levels, as a first-line therapy for treatment-naïve patients with advanced NSCLC […] Read more
Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC
Beth Fand IncollingoNSCLC that harbors more than one DNA damage-response (DDR) gene alteration is more likely to respond to immunotherapy than disease that harbors one or no such mutations. So concluded investigators […] Read more
A significant number of patients with lung cancer did not undergo testing for all relevant biomarkers, according to real-world data from a study in Japan (MA08.08), and use of simultaneous […] Read more
Management of Long-Term Immune-Related Toxicities Needed in NSCLC
Beth Fand IncollingoWhile checkpoint inhibitors have improved the outlook for patients with advanced NSCLC, more information is needed about the long-term toxicities caused by the drugs and how they should be managed. […] Read more
Raising Awareness about Lung Cancer Screening among Minorities, People Who Smoke
Dusty DonaldsonMinorities are at significantly higher risk for developing lung cancer than whites, even with the same smoking history. In an attempt to, in part, address this disparity, the U.S. Preventive […] Read more
Additional ADAURA Analyses Help Support the Benefit of Adjuvant Osimertinib in Patients With Resected EGFR-Mutated NSCLC
Kara Nyberg, PhDThe randomized phase III ADAURA trial stirred up considerable excitement last year when results from an unplanned interim analysis revealed an 80% reduction in the risk of disease recurrence or […] Read more
Lung Cancer Screening for Women: Understanding the Risks and the Benefits
Dusty DonaldsonAlthough science has proven that both men and women significantly benefit from lung cancer screening by low-dose CT, the NELSON study showed that women benefit substantially more than men.1 However, […] Read more